Bayer will pay $400 million -- and up to $1.15 million more in milestones tied to regulatory approvals and sales -- for partial commercial rights to two rare cancer drugs being developed by Loxo ...

Achieving excellence in oncology franchises is driving large-cap companies to make astute buys of relatively smaller-sized companies with breakthrough pipeline assets in the field. Eli Lilly And Co ...

As researchers look for new approaches for tough-to-treat cancer, many are looking into genetics — more specifically, they're looking at the type of genetic mutations found in cancerous tumors. One ...

"We look to generate crazy over-the-top exciting data that is great for patients,” Loxo CEO Josh Bilenker, pictured alongside chief business officer Jacob Van Naarden (left), told Forbes last year. A ...

The FDA recently approved Loxo Oncology's first new drug application, making Vitrakvi the first cancer treatment the agency's approved to treat a tumor-agnostic indication right off the bat. Keytruda ...

STAMFORD, Connecticut (Reuters) - In record time, Loxo Oncology developed a novel drug for a wide variety of tumors that share a rare mutation. It recently struck a partnership with Germany's Bayer.

When Eli Lilly announced during the recent J.P. Morgan Healthcare Conference that it would buy Loxo Oncology for $8 billion—a 68% premium—some analysts assumed there must have been a bidding war for ...

DXC Technology (NYSE:DXC) has entered a partnership with LOXO to bring autonomous logistics solutions to commercial fleets. The collaboration focuses on combining LOXO's Level 4 autonomy platform with ...

Eli Lilly’s $8 billion purchase of Loxo Oncology in January wasn’t supposed to be a tech-style acqui-hire. But it’s turning into one. On Thursday, the drug giant announced that it is renaming its ...

Precision medicine that targets specific mutations in DNA to better combat cancer is a major area of drug research and development and Loxo Oncology's at the forefront of this approach. Viktravi won a ...

Shares of Loxo Onocology Inc. were indicated up about 33% in premarket trade Monday, after the biopharmaceutical company agreed to be acquired by Eli Lilly & Co. in a deal valued at $8.0 billion.

The pharma giant Eli Lilly & Co. on Monday said it planned to buy the biotech Loxo Oncology for $8 billion in cash. It's an unusually large acquisition for Eli Lilly that also represents a massive bet ...